Hillel S Panitch
Affiliation: University of Vermont
- Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trialHillel Panitch
University of Vermont College of Medicine, Neurology Health Care Service, 1 South Prospect Street, Burlington, VT 05401, USA
J Neurol Sci 239:67-74. 2005..The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes...
- Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE TrialH Panitch
University of Vermont College of Medicine, Burlington, VT 05401, USA
Neurology 59:1496-506. 2002..Interferon beta (IFNbeta) reduces relapses and MRI activity in relapsing-remitting MS (RRMS), with variable effects on disability. The most effective dose regimen remains controversial...
- Interferon beta-1b in secondary progressive MS: results from a 3-year controlled studyHillel Panitch
University of Vermont, College of Medicine, Burlington 05401, USA
Neurology 63:1788-95. 2004..To evaluate the efficacy and safety of interferon beta-1b (IFNbeta-1b) in subjects with secondary progressive multiple sclerosis (SPMS)...
- Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosisHillel S Panitch
Neurology Health Care Service, Fletcher Allen Health Care, University of Vermont, Burlington, 05401, USA
Ann Neurol 59:780-7. 2006....
- Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapSteven R Schwid
Department of Nuerology, University of Rochester, Rochester, New York 14642, USA
Clin Ther 29:2031-48. 2007..Interferon (IFN)-beta therapy represents an important advance in the management of relapsing multiple sclerosis (MS), but information about the relative benefits and risks of available preparations is limited...